Skip to main content
spacbrain

SAB Biotherapeutics

Closed (deSPAC)

Health Care · biopharmaceutical immunotherapy development

What it is
Biotherapeutics, Inc
What it’s doing now
Merging with Big Cypress Acquisition Corp. (BCYP) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Biotherapeutics, Inc. SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies with a focus on building a leading immune and autoimmune disorders pipeline. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.SAb.bio/and follow SAB on Twitter and LinkedIn.

Source: S-4/A, accession 0001493152-21-023292

The deal it’s entering

SAB Biotherapeutics is merging with Big Cypress Acquisition Corp. (BCYP) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is SAB Biotherapeutics going public?

SAB Biotherapeutics has an approved merger with the SPAC Big Cypress Acquisition Corp. (BCYP). Deal status: Closed (deSPAC).

Does SAB Biotherapeutics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals